INTRODUCTION
Aspirin with a dose of 75-150 mg daily has been found to reduce risk of vascular events by approximately 32% in patients with cardiovascular disease (CVD) [1] . However, a substantial number of patients do not respond optimally to aspirin treatment [2] . The inter-individual variability of patients' responses is due to variation either in pharmacokinetic (PK) or pharmocodynamic (PD) properties of aspirin [3] . Those polymorphic enzymes potentially affecting the PK-PD of aspirin include cyclooxygenase-1 (COX-1), UDPglucuronosyltransferase 1A6 (UGT1A6) and CYP2C9 enzymes.
COX-1 is directly and irreversibly inhibited by aspirin resulting in reduction or inhibition of the formation of precursors of prostaglandins and thromboxanes. Genetic variants of COX-1 gene were suggested to modulate arachidonic acidinduced platelet aggregation and serum thromboxane B2 (TXB2) levels in patients treated with aspirin. The Polymorphic UDPglucuronosyltransferase (UGT1A6) and CYP2C9*3 enzymes are reported to be associated with altered enzyme function which affects aspirin metabolism and efficacy. . The amino acid changes for two variants of UGT1A6 (UGT1A6*2; A541G and UGT1A6*3; A522C) result in a 30%-50% reduced enzyme activity compared to enzyme encoded by the wild-type allele [4] . Both variants of UGT1A6*2 and *3 are in complete linkage disequilibrium [5] . The variant alleles for CYP2C9*3 also produce enzymes bearing some 5%-30% of the activity of the wild-type enzyme [6] . All these polymorphic enzymes might modulate the therapeutic effect of aspirin in treatment or prevention of CVD. Carriers of variant alleles are more prone to develop acute gastrointestinal problems when they receive aspirin as compared to non-carriers [7, 8] .
Several biochemical tests are routinely screened among the patients in order to assess the risk of early stage CVD. Altered Lipid profiles which includes HDL, LDL, trigylcerides and total cholesterol are common risk factors for CVD. The higher the cholesterol level, the higher the risk of CVD disease. However, HDL is "good cholesterol" which protects one against the disease by removing cholesterol and excess fat from blood vessel walls and transports them to the liver to be removed from the body. Besides, there is an apparent protective effect of bilirubin which is in similar magnitude as HDL. A study shows that a 50% decrease in total bilirubin was associated with a 47% increased risk of having more severe coronary artery disease (p=0.02) [9] . Since, UDP-glucuronosyltransferase (UGT1A6) is highly expressed in liver and plays a major role in the metabolisms of bilirubin, their genetic polymorphisms and bilirubin levels are potentially important risk factors of CVD.
The aims of this study were to investigate the relationship between the clinical parameters and genetic polymorphisms of COX-1, UGT1A6 and CYP2C9 in cardiovascular patients. This allows the assessment of the impact of genetic polymorphisms of COX-1, UGT1A6 and CYP2C9 on gastritis or other gastrointestinal symptoms in cardiovascular patients treated with aspirin.
METHODS

Subjects
The protocol of the study was approved by the local Research and Ethics Committee. The study comprised of 165 patients and 300 healthy volunteers aged 18 to 65 years old. All patients were diagnosed with cardiovascular disease and treated with aspirin (acetylsalicylic acid, 75-150 mg daily dose); while the healthy volunteers were unrelated individuals not receiving any treatment. All the participants were healthy mentally and physically, understand the study protocol and willing to sign the consent form.
Data Collection
Medical records for all patients were reviewed. The clinical data include medical history, biochemical test result (i.e. liver function test, renal function test, full blood count, lipid profile and blood glucose), dosage regimen, INR measurement, concurrent drugs intake and adverse effects experienced by patients were recorded. Sign and symptoms of gastritis such as gastric pain, vomiting and loss of appetite were reviewed and diagnosed by the medical doctors in charged.
Genotyping
Five milliliters of blood samples were drawn into tubes which contained tri-sodium citrate (4%).The blood samples were used for DNA extraction and genotyping for variants of UGT1A6, COX-1 and CYP2C9. The DNA was extracted using lysis method that has been optimized previously [10] . The extracted DNA was dissolved in 1x TE buffer and kept at -20 ºC freezer until use. Allele specific PCR (AS-PCR) method was developed for detection of each variant. This technique is based on single-nucleotide variations which introduced destabilizing mismatch at the 3' end of the allelespecific primers [11] .
A nested PCR was developed to amplify COX-1(A-842G) variants. Amplicon sizes for the first step PCR and allele specific COX-1(A-842G) variant are 369 bp and 150 bp, respectively. The optimal primer concentrations used was 0.2 μM for common forward (5'-GGTGATCTTGGACCTATTCC-3') and reverse (5'-CTTGGACAAGGTACTTATCTT-3') primers; 0.3 μM for variant (5'-GCACCTACTACATGCTGTG -3') and wild-type (5'-GCACCTACTACATGCTGTA-3') primers. The thermal cycling condition comprised of 30 cycles of 1 st step and 15 cycles for the 2 nd step PCR reaction. DNA denaturing was set at temperature of 94ºC for 30 seconds, while annealing and extension steps were set at 50ºC for 30 seconds and 72ºC for For CYP2C9*3, the amplified fragments for internal control and allele specific are 250 bp and 470 bp, respectively (Figure 1 (d) ). The fragments were amplified using specific primers (variants type forward primer, 5'-CGAGGTCCAGAGATACC-3', 0.3 µM; reverse primer, 5'-CCTCAACGTGTCAAGATTCAGT-3', 0.2 µM); and wild-type forward primer, 5'-CGAGGTCCAGAGATACA-3', 0.3 µM; reverse primer, 5'-CCTCAACGTGTCAAGATTCAGT-3', 0.2 µM). The thermal cycling conditions were the same as for amplification of variants of COX-1 and UGT1A6, but the optimum annealing temperature was 55ºC. For confirmation of the results, PCR products for each variants were sequenced using direct sequencing approach. The sequencing results are illustrated in Figure 1 . 
RESULTS
Three hundred healthy volunteers, 100 each of Malays, Chinese and Indians were recruited. A total number of 165 patients with cardiovascular disease (CVD) who met the inclusion and exclusion criteria of the study were also recruited. Most of the CVD patients were male (84.52%) and the remaining were female (15.48%). About 86.67% of the total patients were overweight and most of them were smokers (59.39%); 75.15% of the patients have dyslipidaemia (Table 1) . The association between genotype and gastritis event among patients who took aspirin as their anticoagulant drug were calculated using chisquare test. The odds ratio (OR) was used to examine the risk of each genotype in association with the development of gastritis event. Referring to the odds ratios in Table 4 , individual who were heterozygous CYP2C9* 3 genotype shows 6.8 times more likely to have gastritis when compared to the individual with homozygous wild-type. Haplotypes was analysed using haploview which was downloaded from http://www.broadinstitute.org/haploview. This software was used to observe the linkage between two UGT1A6 variants (*2 and *3). This analysis was done for the three major ethnic groups in Malaysian population which are the Malays, Chinese and Indians. A hundred samples from each ethnic group were used to study the degree of linkage between the three ethnic groups. As shown in Table 5 , Indians have a strong degree of linkage disequilibrium with D' value of 1. Both variants were found in different percentage of linkage disequilibrium for different ethnic groups, which are 95%, 81% and 100% in Malay, Chinese and Indian ethnic groups, respectively (Table 5) .
DISCUSSION
Most of the smokers were males and this is in line with the high number of male smokers (2.61 million) in Malaysia compared to 120,000 female smokers [13, 14] . The latest projections indicate that approximately 3.1 million smokers were between 25 and 64 years in Malaysia. The Malays constitute the largest number of smokers in Malaysia, with 60.9% [15] . This situation might provide one of the reasons why the Malays tends to have higher incidences of CVD at earlier age compared to the Chinese.
Among 165 patients with CVD in this study, 86.67% were overweight and 75.15% have dyslipidemia. Singh et al. [16] have suggested that obesity and dyslipidemia are related and play major roles in the development of CVD. In addition, this study also showed that there was a significant difference in the lipid profile between the Malays and two other ethnic groups, which was in agreement with the results of Khoo et al. [17] . Further, there was also a significant association between body weight and ethnicity (p = 0.007), where the BMI of the Malays were higher. This finding is supported by Malaysia's National Health and Morbidity Survey 2 (1996 -1997) which found that obesity was significantly associated with ethnicity. This observation may be explained by differences in dietary habits or lifestyle, or by genetic factors between the three ethnic groups.
PT and INR values of the Malay patients were found to be significantly different when compared with the values observed in the Indian and Chinese (p values of 0.016 and 0.014, respectively). The differences of PT and INR may be affected by daily diet. According to Rombout et al. [18] , an increase in the amount of food rich in vitamin K can lower the PT and INR of an individual. Green and leafy vegetables such as broccoli, lettuce and spinach are part of the routine diet of the Chinese ethnic group in Malaysia and therefore it is not surprising for the Chinese to have lower PT and INR values [19] .
Halushka et al. [20] have found that heterozygocity of COX-1 (A-842G) gene significantly shows greater inhibition in the formation of prostaglandin H 2 by acetylsalicylic acid compared with common homozygous wildtype allele. Unfortunately this variant is not detected in this study, even though it was detected at a high percentage among the Caucasians (19% heterozygous and 1% homozygous) [20, 5] . Nagar et al., (2004) reported that the frequencies of UGT1A6*2 and UGT1A6*3 were 5.7% and 5.2% in Caucasian and, 10% and 5% in African-American [21] . The percentage frequency of UGT1A6*2 and UGT1A6*3 for the Chinese population in China were 22% and 24.7%, respectively [22] . Similarly, in the Japanese, UGT1A6*2 and UGT1A6*3 were present in 21.8% and 2.26%, respectively in the population, [23] . Limenta et al. [24] reported that UGT1A6 variants were found in 19% of the Thailand population. The percentage of UGT1A6 variants reported in this study was somewhat consistent with findings among the Chinese in China and Japanese population. Both variants of UGT1A6 were reported to be in complete linkage-disequilibrium of >98% [5] ; while in this study, the linkage was found to be 94%.
The significant association between the concentration of the patients' bilirubin and UGT1A6*2 and *3 was in accordance with a previous finding by Peters et al. [25] . From the existing evidence, the concentration of bilirubin in patients with CVD was associated with the enzyme activity of UGT1A6. As shown in our results, higher concentration of bilirubin was found in patients who possess variants allele of UGT1A6 with slow metabolizing capacity. In other studies by Djousse et al. [26] and Lin et al. [27] , high levels of bilirubin was associated with decreased risks of coronary heart disease (CHD) and cardiovascular disease (CVD). Similarly in the Framingham Offspring Study, higher serum bilirubin concentrations were associated with decreased risk of CVD, CHD, and myocardial infarction (MI) [28] . The association between the genetic polymorphisms of UGT1A6 and the concentration of bilirubin are interesting finding and a case-control study with longer follow-up time might be useful to confirm the relationship.
Homozygous genotype of CYP2C9*3 was reported to present at low frequency of only 1% in the Malay and Indian population [29] , but no homozygous CYP2C9*3 was found in this study. There were also no subjects with homozygous CYP2C9*3 in the 115 Han Chinese as well as 218 Japanese and 98 Taiwanese [30] [31] [32] . The genotype frequency of CYP2C9*3 in this study is in agreement with the reported rare frequency in most population worldwide.
Similar with findings from Van Oijen et al. [5] , no significant association between the occurrence gastric events and polymorphisms of UGT1A6 gene in aspirin treated patients were detected. However, there was a significant association between the slow metabolizer (SM) of heterozygous CYP2C9*3 with the gastritis events among the CVD patients treated with aspirin. There were 25% occurrences of gastritis in patients with heterozygous CYP2C9*3 while only 4.67% of gastric event among patients with homozygous wild type. Martin et al., [33] revealed that 30% of NSAID treated subjects experienced ulceration event in non-wild type CYP2C9 genotypes. The calculated odd ratios (OR) in this study indicated that individuals who were taking aspirin and with heterozygous CYP2C9*3 genotype have 6.8 times higher risk to get gastritis as compared to the individual with homozygous wild-type (p-value 0.033).
CONCLUSION
In conclusion, we have successfully developed allele specific PCR (AS-PCR) methods for detection of COX-1 (A-842G), UGT1A6*2 and *3 and CYP2C9 (A1075C) alleles. Besides, we also have successfully genotyped all the 165 patients and 300 healthy volunteers.
There was an association between the bilirubin concentration of CVD patients and variants of UGT1A6*2 and *3 gene. In addition, this study also found an association of CYP2C9*3 variant allele (slow metabolizer of aspirin) with the occurrence of gastritis event among CVD patients treated with aspirin.
This study provides support to recommend genotyping of CVD patients for UGT1A6*2 and *3 and CYP2C9*3. However, further studies are needed to confirm the association between the genetic polymorphisms of UGT1A6 with the concentration of bilirubin. A case-control study with longer follow-up period might be useful to provide answers to the relationship. In addition, the potential of bilirubin as therapeutic target or tool in monitoring the disease of CVD patients, a clear cut-off concentration or range of normal bilirubin concentration need to be established. Case controlled studies using bigger sample size is required.
